BIRMINGHAM, Ala., July 18, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, announced today that it will host an investor day on September 27, 2023. The event, which will be held in the Rainbow Room in New York City, will begin at 8:30 a.m. ET.
The event will feature presentations and a Q&A session with President & Chief Executive Officer Mark Tarr; Executive Vice President & Chief Financial Officer Doug Coltharp; and other members of the Company's leadership team. Due to limited capacity, investors and analysts who would like to attend must register with Encompass Health's investor relations department via the following link https://encompass-health-ir-day-2023.open-exchange.net/registration or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it..
For those unable to attend in person, live and recorded webcasts of the investor day presentation and accompanying materials will be available at https://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 158 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Casey Winger | 205 447-6410
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$126.05 |
Daily Change: | -0.75 -0.59 |
Daily Volume: | 448,002 |
Market Cap: | US$12.700B |
August 07, 2025 August 04, 2025 June 18, 2025 April 24, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load